Cognitive
Selank
TP-7 · tuftsin analog
Top nootropic-peptide searches ('Selank vs Semax'); marketed as a non-stimulant, non-dependence benzo alternative.
Evidence
Bhuman trials
Status
Category 2 — restrictedas of 2026-06
Approval
Not approved
Category
Cognitive
Route
Intranasal · Subcutaneous
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
Intranasal ~300-450 mcg/day (Russian label); SubQ is community-only
Titration
Cycles ~14 days then washout
Reconstitution — illustrative, not a recommendation
SubQ (community): 5 mg vial + 2 mL BAC = 2.5 mg/mL; 250 mcg = 10 U on U-100. Intranasal is the trial route - dose by mcg/spray.
Reconstitution calculatorlive tool
10units
on a U-100 syringedraw to the 10 mark
Concentration2.5 mg/mL
Draw volume0.1 mL
Illustrative, not a recommendation. mg vs mcg confusion drives 5–1000× overdoses — always recompute for your own vial and syringe.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. No active US compounding pathway; treat as gray-market RUO. Verify against FDA docket.
Status
Category 2 — restricted
503A bulks
Not on the bulks list
Category 2
Removed earlier (Sept 2024 referral) but NOT in the Apr 2026 wave or Jul 2026 PCAC; vendor 'returned to Category 1' claims are FALSE
PCAC review
none scheduled
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows
Small Russian human data (Medvedev 2008, n=62: anxiolytic comparable to benzodiazepine); unreplicated in the West. Russia-approved nasal drops since 2009.
04Safety
Contraindications
- Pregnancy/breastfeedinghard stop
- Children
- Hypersensitivity
Key interactions
- Serotonergic agents (SSRI/SNRI/MAOI) - theoretical serotonin-syndrome additive risk (caution, low confidence)
- Benzodiazepines (animal-derived synergy claim - extrapolation)
Serious signals
- Long-term safety unknown (longest trials ~30 days)
- Gray-market integrity/immunogenicity
Monitoring
None validated.
05Related in Cognitive
06Sources
The primary sources behind this monograph — each opens the registry so you can verify the claim yourself. Last verified 2026-06-13.
Peer-reviewedMedvedev 2008Evidence — peer-reviewed studyHow we source & verify — the full method →Beyond these primaries, every monograph is distilled from TrackurStack’s research dossier — 584 de-duplicated sources across 4 research iterations, adversarially verified against primary sources.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium